174 related articles for article (PubMed ID: 23101592)
61. Comprehensive Analysis of Fragile X Syndrome: Full Characterization of the FMR1 Locus by Long-Read Sequencing.
Liang Q; Liu Y; Liu Y; Duan R; Meng W; Zhan J; Xia J; Mao A; Liang D; Wu L
Clin Chem; 2022 Dec; 68(12):1529-1540. PubMed ID: 36171182
[TBL] [Abstract][Full Text] [Related]
62. Validation of a Commercially Available Screening Tool for the Rapid Identification of CGG Trinucleotide Repeat Expansions in FMR1.
Lim GX; Loo YL; Mundhofir FE; Cayami FK; Faradz SM; Rajan-Babu IS; Chong SS; Koh YY; Guan M
J Mol Diagn; 2015 May; 17(3):302-14. PubMed ID: 25776194
[TBL] [Abstract][Full Text] [Related]
63. Early detection of fragile X syndrome: applications of a novel approach for improved quantitative methylation analysis in venous blood and newborn blood spots.
Inaba Y; Schwartz CE; Bui QM; Li X; Skinner C; Field M; Wotton T; Hagerman RJ; Francis D; Amor DJ; Hopper JL; Loesch DZ; Bretherton L; Slater HR; Godler DE
Clin Chem; 2014 Jul; 60(7):963-73. PubMed ID: 24778142
[TBL] [Abstract][Full Text] [Related]
64. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome.
Straub D; Schmitt LM; Boggs AE; Horn PS; Dominick KC; Gross C; Erickson CA
Sci Rep; 2023 Mar; 13(1):3808. PubMed ID: 36882476
[TBL] [Abstract][Full Text] [Related]
65. FMR1 gene mutation screening by TP-PCR in patients with premature ovarian failure and fragile-X.
Tural S; Tekcan A; Kara N; Elbistan M; Güven D; Ali Tasdemir H
Gynecol Endocrinol; 2015 Mar; 31(3):191-5. PubMed ID: 25366135
[TBL] [Abstract][Full Text] [Related]
66. Validation of Fragile X Screening in the Newborn Population Using a Fit-for-Purpose FMR1 PCR Assay System.
Lee S; Taylor JL; Redmond C; Hadd AG; Kemppainen JA; Haynes BC; Shone S; Bailey DB; Latham GJ
J Mol Diagn; 2020 Mar; 22(3):346-354. PubMed ID: 31866572
[TBL] [Abstract][Full Text] [Related]
67. Implication of screening for FMR1 and FMR2 gene mutation in individuals with nonspecific mental retardation in Taiwan.
Tzeng CC; Tzeng PY; Sun HS; Chen RM; Lin SJ
Diagn Mol Pathol; 2000 Jun; 9(2):75-80. PubMed ID: 10850542
[TBL] [Abstract][Full Text] [Related]
68. Fragile X Syndrome: Scientific Background and Screening Technologies.
Lyons JI; Kerr GR; Mueller PW
J Mol Diagn; 2015 Sep; 17(5):463-71. PubMed ID: 26162330
[TBL] [Abstract][Full Text] [Related]
69. Identification of small FRAXA premutations.
Francis D; Burgess T; Mitchell J; Slater H
Mol Diagn; 2000 Sep; 5(3):221-5. PubMed ID: 11070156
[TBL] [Abstract][Full Text] [Related]
70. Screening for fragile X syndrome.
Murray J; Cuckle H; Taylor G; Hewison J
Health Technol Assess; 1997; 1(4):i-iv, 1-71. PubMed ID: 9414543
[TBL] [Abstract][Full Text] [Related]
71. A 15-year case-mix experience for fragile X syndrome molecular diagnosis and comparison between conventional and alternative techniques leading to a novel diagnostic procedure.
Esposito G; Ruggiero R; Savarese G; Savarese M; Tremolaterra MR; Salvatore F; Carsana A
Clin Chim Acta; 2013 Feb; 417():85-9. PubMed ID: 23279920
[TBL] [Abstract][Full Text] [Related]
72. Defining the Performance Parameters of a Rapid Screening Tool for FMR1 CGG-Repeat Expansions Based on Direct Triplet-Primed PCR and Melt Curve Analysis.
Rajan-Babu IS; Lian M; Tran AH; Dang TT; Le HT; Thanh MN; Lee CG; Chong SS
J Mol Diagn; 2016 Sep; 18(5):719-730. PubMed ID: 27375073
[TBL] [Abstract][Full Text] [Related]
73. A PCR-based test suitable for screening for fragile X syndrome among mentally retarded males.
Haddad LA; Mingroni-Netto RC; Vianna-Morgante AM; Pena SD
Hum Genet; 1996 Jun; 97(6):808-12. PubMed ID: 8641701
[TBL] [Abstract][Full Text] [Related]
74. FMR1 protein expression in blood smears for fragile X syndrome diagnosis in a Mexican population sample.
Romero-Espinoza P; Rosales-Reynoso MA; Willemsen R; Barros-Núñez P
Genet Test Mol Biomarkers; 2010 Aug; 14(4):511-4. PubMed ID: 20642356
[TBL] [Abstract][Full Text] [Related]
75. A 15-year-long Southern blotting analysis of FMR1 to detect female carriers and for prenatal diagnosis of fragile X syndrome in Taiwan.
Tzeng CC; Tsai LP; Chang YK; Hung YJ; Chang YY; Su YP; Jiang JJ; Liang HM
Clin Genet; 2017 Aug; 92(2):217-220. PubMed ID: 28139839
[TBL] [Abstract][Full Text] [Related]
76. Mosaicism for FMR1 gene full mutation and intermediate allele in a female foetus: a postzygotic retraction event.
Ferreira SI; Pires LM; Ferrão J; Sá J; Serra A; Carreira IM
Gene; 2013 Sep; 527(1):421-5. PubMed ID: 23792063
[TBL] [Abstract][Full Text] [Related]
77. Methylation analysis of the fragile X syndrome by PCR.
Das S; Kubota T; Song M; Daniel R; Berry-Kravis EM; Prior TW; Popovich B; Rosser L; Arinami T; Ledbetter DH
Genet Test; 1997-1998; 1(3):151-5. PubMed ID: 10464640
[TBL] [Abstract][Full Text] [Related]
78. Screening for fragile X syndrome in males from specialized institutions in the northeast region of Brazil.
Viveiros MT; Santos MD; Dos Santos JM; Viveiros DM; Cavalcante MR; Caldas AJ; Pimentel MM
Genet Mol Res; 2015 Jun; 14(2):6897-905. PubMed ID: 26125897
[TBL] [Abstract][Full Text] [Related]
79. Coexistence of Fragile-X Syndrome, 8p23.1 Deletion, and Balanced Translocation t(7;10)(p10;q24) in a Single Family.
Cortés H; Reyes-Rosales M; Rojas-Velasco AJ; García-Juárez B; Tapia-Guerrero YS; Arenas-Diaz S; Leyva-García N; Macías-Gallardo JJ; Carrillo-Mora P; Magaña JJ
Genet Test Mol Biomarkers; 2020 Aug; 24(8):527-531. PubMed ID: 32716213
[No Abstract] [Full Text] [Related]
80. Fragile X molecular investigation and genetic counseling of intellectual disability/developmental delay patients in an Indian scenario.
Dean DD; Agarwal S; Muthuswamy S
Expert Rev Mol Diagn; 2019 Jul; 19(7):641-649. PubMed ID: 31159589
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
